NuPathe Zelrix Patch receives FDA rejection
According to FDA, the data provided by the company was insufficient regarding migrane indication, painmedicinenews.com reported. NuPathe conducted a Phase III trial testing the efficacy of the transdermal
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
The pharmacy automation solution is said to optimize medication ordering, dispensing, administration, charge capture, and inventory management processes. In addition, the medical center is also using McKesson’s ROBOT-Rx